Remove 2030 Remove Disease Remove Virus
article thumbnail

mRNA Tech Transfer Phase 2.0 Discussed at G20 Summit

The Pharma Data

2026–2030). Importantly, this will enable them to produce mRNA vaccines during periods between health crises, retaining trained personnel, technical expertise, and production capacity while retaining the ability to respond quickly in the event of future disease outbreaks.

article thumbnail

FDA Approves Expanded Use of AbbVie’s MAVYRET for Acute Hepatitis C

The Pharma Data

With this approval, MAVYRET becomes the first and only DAA treatment approved to treat both acute and chronic hepatitis C virus (HCV) infections in patients as young as three years old, with or without compensated cirrhosis, using an eight-week regimen. No one should die of hepatitis C.” However, progress toward that target has been slow.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Immunization at Every Stage of Life: A Key to Lifelong Health

The Pharma Data

By 2030, nearly one billion people will fall into the 65-and-older age group, marking a seismic shift in age distribution across the world. Despite the fact that vaccine-preventable diseases pose significant risks across the lifespan, adult immunization remains underutilized and inconsistently prioritized.

article thumbnail

Bayer to launch Vynyty Citrus®, its newest biological product to control citrus farm pests during virtual symposium

The Pharma Data

This biological solution responds to Bayer’s commitment to help reduce the environmental impact of crop protection by 30% by 2030 without reducing crop yields. The launch of Vynyty Citrus ® at this year’s SHE2021 event coincides with 2021 being designated as the International Year of Fruits and Vegetables by the United Nations.

article thumbnail

Roche awarded WHO prequalification for the HIV and HCV tests on the cobas 6800/8800 Systems

The Pharma Data

Access to broader reliable diagnostic solutions helps healthcare communities working to expedite and increase disease elimination programs. Roche’s Global Access Program provides innovative diagnostic solutions improving disease and patient ma. Without accurate diagnosis, appropriate disease management may be delayed.

article thumbnail

COVAX ANNOUNCES ADDITIONAL DEALS TO ACCESS PROMISING COVID-19 VACCINE CANDIDATES; PLANS GLOBAL ROLLOUT STARTING Q1 2021

The Pharma Data

billion: Norway has signed a new commitment of NOK 1 billion to the International Finance Facility for Immunisation (IFFIm), to be paid from 2021 to 2030. Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world’s children against some of the world’s deadliest diseases.

article thumbnail

World Health Assembly charts course for COVID-19 response and global health priorities

The Pharma Data

Since May, Member States have adopted a number of decisions – the Immunization Agenda 2030, the Decade of Healthy Ageing 2020-2030, as well as initiatives to tackle cervical cancer, tuberculosis, eye care, food safety, intellectual property and influenza preparedness. The WHA will consider a draft resolution ( EB146.R10